Find Emricasan manufacturers, exporters & distributors on PharmaCompass

Emricasan

Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

DEVELOPMENTS

2 Drugs in Development

2 Drugs in Development

DIGITAL CONTENT

5 NEWS #PharmaBuzz

media
5 NEWS #PharmaBuzz

Synopsis

ACTIVE PHARMA INGREDIENTS

API Suppliers

USDMF

CEP/COS

JDMF

EU WC

KDMF

NDC API

VMF

Listed Suppliers

API REF. PRICE (USD/KG)

$ 0

MARKET PLACE

API

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

FDF Dossiers

FDA Orange Book

Europe

Canada

Australia

South Africa

Listed Dossiers

2DRUGS IN DEVELOPMENT

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

EDQM

USP

Others

PATENTS & EXCLUSIVITIES

US Patents

US Exclusivities

Health Canada Patents

DIGITAL CONTENT

Data Compilation #PharmaFlow

Stock Recap #PipelineProspector

Weekly News Recap #Phispers

News #PharmaBuzz

GLOBAL SALES INFORMATION

US Medicaid (USD)

Annual Reports (USD Million)

Finished Drug Prices

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown

Click the button for full data set

Also known as: 254750-02-2, Idn-6556, Pf-03491390, Pf 03491390, (s)-3-((s)-2-(2-(2-tert-butylphenylamino)-2-oxoacetamido)propanamido)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid, Idn 6556

Molecular Formula

C₂₆H₂₇F₄N₃O₇

Molecular Weight

569.5 g/mol

InChI Key

SCVHJVCATBPIHN-SJCJKPOMSA-N

FDA UNII

P0GMS9N47Q

Emricasan is the first caspase inhibitor tested in human which has received orphan drug status by FDA. It is developed by Pfizer and made in such a way that it protects liver cells from excessive apoptosis.

1 2D Structure

Emricasan

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

(3S)-3-[[(2S)-2-[[2-(2-tert-butylanilino)-2-oxoacetyl]amino]propanoyl]amino]-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid

2.1.2 InChI

InChI=1S/C26H27F4N3O7/c1-12(31-24(38)25(39)32-16-8-6-5-7-13(16)26(2,3)4)23(37)33-17(10-19(35)36)18(34)11-40-22-20(29)14(27)9-15(28)21(22)30/h5-9,12,17H,10-11H2,1-4H3,(H,31,38)(H,32,39)(H,33,37)(H,35,36)/t12-,17-/m0/s1

2.1.3 InChI Key

SCVHJVCATBPIHN-SJCJKPOMSA-N

2.1.4 Canonical SMILES

CC(C(=O)NC(CC(=O)O)C(=O)COC1=C(C(=CC(=C1F)F)F)F)NC(=O)C(=O)NC2=CC=CC=C2C(C)(C)C

2.1.5 Isomeric SMILES

C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)COC1=C(C(=CC(=C1F)F)F)F)NC(=O)C(=O)NC2=CC=CC=C2C(C)(C)C

2.2 Other Identifiers

2.2.1 UNII

P0GMS9N47Q

2.3 Synonyms

2.3.1 MeSH Synonyms

1. 3-(2-(2-tert-butylphenylaminooxalyl)aminopropionylamino)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic Acid

2. Idn 6556

3. Idn-6556

4. Idn6556

5. Pf 03491390

6. Pf-03491390

7. Pf03491390

2.3.2 Depositor-Supplied Synonyms

1. 254750-02-2

2. Idn-6556

3. Pf-03491390

4. Pf 03491390

5. (s)-3-((s)-2-(2-(2-tert-butylphenylamino)-2-oxoacetamido)propanamido)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic Acid

6. Idn 6556

7. (s)-3-((s)-2-(2-((2-(tert-butyl)phenyl)amino)-2-oxoacetamido)propanamido)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic Acid

8. Vay785

9. Vay-785

10. P0gms9n47q

11. (3s)-3-[[(2s)-2-[[2-(2-tert-butylanilino)-2-oxoacetyl]amino]propanoyl]amino]-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic Acid

12. L-alaninamide, N-(2-(1,1-dimethylethyl)phenyl)-2-oxoglycyl-n-((1s)-1-(carboxymethyl)-2-oxo-3-(2,3,5,6-tetrafluorophenoxy)propyl)-

13. Emricasan [usan]

14. Emricasan [usan:inn]

15. Unii-p0gms9n47q

16. C26h27f4n3o7

17. Emricasan [inn]

18. Emricasan(idn6556)

19. Emricasan (usan/inn)

20. Emricasan [who-dd]

21. Chembl197672

22. Gtpl6508

23. Schembl3288801

24. Dtxsid10180160

25. Amy36447

26. Bcp07463

27. Ex-a1659

28. Bdbm50461533

29. S7775

30. Zinc14191207

31. Akos016009462

32. Ccg-270089

33. Cs-0599

34. Db05408

35. Ncgc00346477-01

36. Ac-31507

37. As-75073

38. Hy-10396

39. Pf03491390

40. Emricasan(idn6556,pf03491390)

41. J3.566.323a

42. D10004

43. Emricasan (idn-6556, Pf-03491390)

44. A857136

45. Q27077178

46. (3s)-3-((2s)-2-((n-(2-tert-butyl)phenyl)carbamoyl)carbonylamino) Propanoylamino)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic Acid

47. (3s)-3-(n2-((2-tert-butylphenyl)oxamoyl)-l-alaninamido)-4-oxo-5-(2,3,5,6- Tetrafluorophenoxy)pentanoic Acid

48. (3s)-3-(n2-((2-tert-butylphenyl)oxamoyl)-l-alaninamido)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic Acid

49. (3s)-3-[(2s)-2-{[(2-tert-butylphenyl)carbamoyl]formamido}propanamido]-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic Acid

50. (3s)-3-[[(2s)-2-[[2-(2-tert-butylanilino)-2-oxo-acetyl]amino]propanoyl]amino]-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic Acid

51. (3s)-3-[[(2s)-2-[[2-[(2-tert-butylphenyl)amino]-2-oxoacetyl]amino]propanoyl]amino]-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic Acid

52. (s)-3-((s)-2-(2-((2-(tert-butyl)phenyl)amino)-2-oxoacetamido)propanamido)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoicacid

2.4 Create Date

2007-02-05

3 Chemical and Physical Properties

Molecular Formula	C₂₆H₂₇F₄N₃O₇
Molecular Weight	569.5 g/mol
XLogP3	3.6
Hydrogen Bond Donor Count	4
Hydrogen Bond Acceptor Count	11
Rotatable Bond Count	11
Exact Mass	569.17851286 g/mol
Monoisotopic Mass	569.17851286 g/mol
Topological Polar Surface Area	151 Å²
Heavy Atom Count	40
Formal Charge	0
Complexity	934
Isotope Atom Count	0
Defined Atom Stereocenter Count	2
Undefined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	0
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	1

4 Drug and Medication Information

4.1 Drug Indication

Investigated for use/treatment in hepatitis (viral, C), liver disease, and transplantation (organ or tissue).

Treatment of non-alcoholic steatohepatitis (NASH)

5 Pharmacology and Biochemistry

5.1 Mechanism of Action

IDN-6556 significantly improves markers of liver damage in patients infected with the Hepatitis C virus (HCV), an infection that affects up to 170m patients worldwide. IDN-6556 represents a new class of drugs that protect the liver from inflammation and cellular damage induced by viral infections and other causes. Various studies have also shown that it significantly lowers aminotransferase activity in HCV patients and appeared to be well tolerated.

Drugs in Development